1-18 of 18
Lars Dyrskjøt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group

Available to Purchase
Alexander W. Wyatt, Saskia Litiere, Francois-Clément Bidard, Luc Cabel, Lars Dyrskjøt, Chris A. Karlovich, Klaus Pantel, Joan Petrie, Reena Philip, Hillary S. Andrews, Paz J. Vellanki, Sofie H. Tolmeijer, Xenia Villalobos Alberu, Christian Alfano, Jan Bogaerts, Emiliano Calvo, Alice P. Chen, Rodrigo A. Toledo, Elisabeth G.E. de Vries, Lesley Seymour, Scott A. Laurie, Elena Garralda, for the RECIST ctDNA workshop group
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5034–5041.
https://doi.org/10.1158/1078-0432.CCR-24-1883
Published: 15 November 2024
View articletitled, Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Open the PDF for Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group in another window
Journal Articles

Abstract PR004: Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment

Free
Trine Strandgaard, Tine Ginnerup Andreasen, Tessa Jane Divita, Liina Salminen, Sean Houghton, Kasper Thorsen, Iver Nordentoft, Iyinyeoluwa Okulate, Alexander Schmitz, Søren Riis Paludan, John Sfakianos, Amir Horowitz, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10_Supplement): PR004.
https://doi.org/10.1158/1557-3265.BLADDER24-PR004
Published: 17 May 2024
View articletitled, Abstract PR004: Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment
Journal Articles

Abstract PR003: T cell receptor repertoire and diversity are prognostic markers in bladder cancer

Free
Nanna Kristjánsdóttir, Asbjørn Kjær, Iver Nordentoft, Randi I Juul, Karin Birkenkamp-Demtröder, Johanne Ahrenfeldt, Trine Strandgaard, Deema Radif, Darren Hodgson, Christopher Abbosh, Hugo JWL Aerts, Mads Agerbæk, Jørgen B Jensen, Nicolai J. Birkbak, Lars Dyrskjøt
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10_Supplement): PR003.
https://doi.org/10.1158/1557-3265.BLADDER24-PR003
Published: 17 May 2024
View articletitled, Abstract PR003: T cell receptor repertoire and diversity are prognostic markers in bladder cancer
Journal Articles

Abstract B008: High expression of the exhaustion markers PD1 and PD-L1 in non-muscle invasive bladder cancer is associated with poor outcome following Bacillus Calmette-Guérin immunotherapy

Free
Tine G. Andreasen, Trine Strandgaard, Jørgen B. Jensen, Lars Dyrskjøt
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10_Supplement): B008.
https://doi.org/10.1158/1557-3265.BLADDER24-B008
Published: 17 May 2024
View articletitled, Abstract B008: High expression of the exhaustion markers PD1 and PD-L1 in non-muscle invasive bladder cancer is associated with poor outcome following Bacillus Calmette-Guérin immunotherapy
Journal Articles

Abstract IA006: Towards ctDNA-guided treatment of muscle-invasive bladder cancer

Free
Lars Dyrskjøt
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10_Supplement): IA006.
https://doi.org/10.1158/1557-3265.BLADDER24-IA006
Published: 17 May 2024
View articletitled, Abstract IA006: Towards ctDNA-guided treatment of muscle-invasive bladder cancer
Journal Articles

Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic

Open Access
Iben Lyskjær, Laura Iisager, Christian Tang Axelsen, Tommy Kjærgaard Nielsen, Lars Dyrskjøt, Niels Fristrup
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 663–672.
https://doi.org/10.1158/1078-0432.CCR-23-1892
Published: 16 February 2024
View articletitled, Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic
Open the PDF for Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic in another window
Journal Articles

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up

Open Access
Sia V. Lindskrog, Karin Birkenkamp-Demtröder, Iver Nordentoft, George Laliotis, Philippe Lamy, Emil Christensen, Derrick Renner, Tine G. Andreasen, Naja Lange, Shruti Sharma, Adam C. ElNaggar, Minetta C. Liu, Himanshu Sethi, Alexey Aleshin, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4797–4807.
https://doi.org/10.1158/1078-0432.CCR-23-1860
Published: 01 December 2023
View articletitled, Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
Open the PDF for Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up in another window
Includes: Supplementary data
Journal Articles

Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer

Open Access
Emil Christensen, Iver Nordentoft, Karin Birkenkamp-Demtröder, Sara K. Elbæk, Sia V. Lindskrog, Ann Taber, Tine G. Andreasen, Trine Strandgaard, Michael Knudsen, Philippe Lamy, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1582–1591.
https://doi.org/10.1158/1078-0432.CCR-22-3250
Published: 14 April 2023
View articletitled, Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Open the PDF for Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder Cancer

Free
Alana Lelo, Frederik Prip, Brent T. Harris, David Solomon, Deborah L. Berry, Krysta Chaldekas, Anagha Kumar, Jeffry Simko, Jørgen Bjerggaard Jensen, Pritish Bhattacharyya, Ciaran Mannion, Jung-Sik Kim, George Philips, Lars Dyrskjøt, Todd Waldman
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4145–4153.
https://doi.org/10.1158/1078-0432.CCR-17-3244
Published: 04 September 2018
View articletitled, STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder Cancer
Open the PDF for STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups

Free
Kim E.M. van Kessel, Kirstin A. van der Keur, Lars Dyrskjøt, Ferran Algaba, Naeromy Y.C. Welvaart, Willemien Beukers, Ulrika Segersten, Bastian Keck, Tobias Maurer, Tatjana Simic, Marcus Horstmann, Marc-Oliver Grimm, Gregers G. Hermann, Karin Mogensen, Arndt Hartmann, Niels Harving, Astrid C. Petersen, Jørgen B. Jensen, Kerstin Junker, Joost L. Boormans, Francisco X. Real, Núria Malats, Per-Uno Malmström, Torben F. Ørntoft, Ellen C. Zwarthoff
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1586–1593.
https://doi.org/10.1158/1078-0432.CCR-17-2719
Published: 02 April 2018
View articletitled, Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups
Open the PDF for Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups in another window
Includes: Supplementary data
Journal Articles

A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine

Free
Raju Kandimalla, Roy Masius, Willemien Beukers, Chris H. Bangma, Torben F. Orntoft, Lars Dyrskjot, Nikki van Leeuwen, Hester Lingsma, Angela A.G. van Tilborg, Ellen C. Zwarthoff
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4760–4769.
https://doi.org/10.1158/1078-0432.CCR-12-3276
Published: 02 September 2013
View articletitled, A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
Open the PDF for A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine in another window
Includes: Supplementary data
Journal Articles

Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers

Free
Thomas Reinert, Charlotte Modin, Francisco M. Castano, Philippe Lamy, Tomasz K. Wojdacz, Lise Lotte Hansen, Carsten Wiuf, Michael Borre, Lars Dyrskjøt, Torben F. Ørntoft
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5582–5592.
https://doi.org/10.1158/1078-0432.CCR-10-2659
Published: 01 September 2011
View articletitled, Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Open the PDF for Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers in another window
Includes: Supplementary data
Journal Articles

Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy

Free
Karina Dalsgaard Sørensen, Peter Johannes Wild, Ashkan Mortezavi, Katja Adolf, Niels Tørring, Sara Heebøll, Benedicte Parm Ulhøi, Peter Ottosen, Tullio Sulser, Thomas Hermanns, Holger Moch, Michael Borre, Torben Falck Ørntoft, Lars Dyrskjøt
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1400–1410.
https://doi.org/10.1158/1078-0432.CCR-08-2268
Published: 19 February 2009
View articletitled, Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy
Open the PDF for Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy in another window
Includes: Supplementary data
Journal Articles

Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer

Free
Anne B. Als, Lars Dyrskjøt, Hans von der Maase, Karen Koed, Francisco Mansilla, Helle E. Toldbod, Jens L. Jensen, Benedicte P. Ulhøi, Lisa Sengeløv, Klaus M.E. Jensen, Torben F. Ørntoft
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4407–4414.
https://doi.org/10.1158/1078-0432.CCR-07-0109
Published: 01 August 2007
View articletitled, Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer
Open the PDF for Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer in another window
Journal Articles

Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study

Free
Lars Dyrskjøt, Karsten Zieger, Francisco X. Real, Núria Malats, Alfredo Carrato, Carolyn Hurst, Sanjeev Kotwal, Margaret Knowles, Per-Uno Malmström, Manuel de la Torre, Kenneth Wester, Yves Allory, Dimitri Vordos, Aurélie Caillault, François Radvanyi, Anne-Mette K. Hein, Jens L. Jensen, Klaus M.E. Jensen, Niels Marcussen, Torben F. Ørntoft
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3545–3551.
https://doi.org/10.1158/1078-0432.CCR-06-2940
Published: 15 June 2007
View articletitled, Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study
Open the PDF for Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study in another window
Includes: Supplementary data
Journal Articles

Molecular Profiling of ADAM12 in Human Bladder Cancer

Free
Camilla Fröhlich, Reidar Albrechtsen, Lars Dyrskjøt, Lise Rudkjær, Torben F. Ørntoft, Ulla M. Wewer
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (24): 7359–7368.
https://doi.org/10.1158/1078-0432.CCR-06-1066
Published: 22 December 2006
View articletitled, Molecular Profiling of ADAM12 in Human Bladder Cancer
Open the PDF for Molecular Profiling of ADAM12 in Human Bladder Cancer in another window
Journal Articles

Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors

Free
Karsten Zieger, Lars Dyrskjøt, Carsten Wiuf, Jens L. Jensen, Claus L. Andersen, Klaus Møller-Ernst Jensen, Torben Falck Ørntoft
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7709–7719.
https://doi.org/10.1158/1078-0432.CCR-05-1130
Published: 08 November 2005
View articletitled, Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors
Open the PDF for Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors in another window
Includes: Supplementary data
Journal Articles

A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome

Free
Lars Dyrskjøt, Karsten Zieger, Mogens Kruhøffer, Thomas Thykjaer, Jens L. Jensen, Hanne Primdahl, Natasha Aziz, Niels Marcussen, Klaus Møller, Torben F. Ørntoft
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (11): 4029–4036.
https://doi.org/10.1158/1078-0432.CCR-04-2095
Published: 01 June 2005
View articletitled, A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome
Open the PDF for A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome in another window
Includes: Supplementary data